Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

Search Cook Medical

Newsroom
June 4th, 2018

Cook Medical, Taewoong Medical partner to distribute stents in the U.S.


Bloomington, Ind. – To complement its existing line of metal GI stents, Cook Medical has partnered with Taewoong Medical to distribute a selection of stents in to the U.S. The new partnership includes the Niti-S™ Through the Scope (TTS) Esophageal Stent, the flagship product of the South Korean company’s Niti-S Self-Expandable line of metal GI stents. Cook Medical will begin distributing the Taewoong portfolio on November 1, 2018.

Esophageal stents are often used in the treatment of esophageal cancer. According to the American Cancer Institute for Cancer Research, there are approximately 17,000 new cases reported annually, the vast majority occurring in men. This year alone, esophageal cancer will claim almost 16,000 lives.

“We’re excited to continue our goal to support physicians in their treatment of diseases of the GI tract by adding Taewoong’s stent technologies to our existing Evolution® and Zilver® stent offerings,” said Barry Slowey, president of Cook Winston-Salem and vice president of Cook Medical’s Endoscopy speciality. “In addition to their product offering, we’re honored to collaborate with Taewoong because we share a commitment to provide solutions that deliver patient care through innovation.”

Unique to the U.S. market, the Niti-S TTS Esophageal Stent is preloaded in a 10.5 Fr delivery system. This allows deployment through a scope with a conical tip designed to navigate tight strictures and tortuous anatomies.

In addition to the Niti-S TTS Esophageal Stent, Cook will also be the U.S. distributor for the Niti-S S Esophageal Stent—a standard esophageal stent—as well as the Niti-S Biliary Stent.

“We are very pleased and proud to enter into this partnership with Cook Medical, a leading global medical device company,” said Kyongmin Shin, CEO of Taewoong Medical. “We believe Cook Medical’s philosophy and focus towards continuous innovation in product development is akin to Taewoong Medical’s own philosophy. And I am confident that our partnership will bring the optimal stent solutions to U.S. doctors and patients.”

About Cook Medical
Since 1963 Cook Medical has worked closely with physicians to develop technologies that eliminate the need for open surgery. Today we are combining medical devices, biologic materials and cellular therapies to help the world’s healthcare systems deliver better outcomes more efficiently. We have always remained family owned so that we have the freedom to focus on what we care about: patients, our employees and our communities. Find out more at www.cookmedical.com, and for the latest news, follow us on Twitter, Facebook and LinkedIn.

About Taewoong Medical
Taewoong Medical Co., Ltd, founded in 1991, is a privately-held company based in Seoul, South Korea. It manufactures a range of medical equipment of its own design: gastrointestinal devices, interventional urology stents and GI accessories. Taewoong is committed to maintaining high levels of innovation, knowledge and technical expertise to deliver solutions to their customers.